Clinical trials: Withdrawal Symptoms
Alcohol-Related Disorders, Alcohol Dependence
Acamprosate to Reduce Symptoms of Alcohol Withdrawal
This study will examine whether a new drug called acamprosate can be helpful for alcohol withdrawal, a result of drinking high amounts of alcohol for long periods of time.
- Conditions
- Alcohol-Related Disorders, Alcohol Dependence, Alcoholism, Healthy Volunteer
- Trial name
- NCT00106106
- Testing
- NMR-spectroscopy, Oral acamprosate
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- National Institutes of Health Clinical Center (CC)
Substance Withdrawal Syndrome
Signs and Symptoms of Opioid-associated Iatrogenic Withdrawal in Critically Ill Adults
Mechanically ventilated critically ill adults may require prolonged administration of opioids to facilitate ventilator support and maintain comfort.
- Trial name
- SOWA-ICU (NCT03435614)
- Testing
- Opioids
- Where
- Canada
- Volunteers
- 29 people
- Sponsor
- Marc M. Perreault
Paroxysmal Atrial Fibrillation
Oral Anticoagulation Therapy Pilot Study
The objective of this study is to determine the safety of discontinuing oral anticoagulation therapy in high risk patients who have had a successful cardiac ablation and remain AF recurrence free for 3 months post ablation.
- Trial name
- OAT (NCT01959425)
- Testing
- Off OAT Group (Test), On OAT Group (Control)
- Volunteers
- 80 people
- Sponsor
- Biosense Webster, Inc.
Nicotine Dependence
Nicotine Replacement Therapy (NRT) and Bupropion Mechanisms of Effectiveness in Smokers
The purpose of this study is to better characterize differences in mood, attention, brain activation patterns underlying the beneficial effects of pharmacological treatments previously demonstrated to be help individuals…
- Trial name
- NCT01048944
- Testing
- Bupropion SR, Nicotine Patch
- Where
- United States
- Volunteers
- 197 people
- Sponsor
- Southern Illinois University Carbondale
Headache
Medication-overuse Headache (MOH): Withdrawal or Use of Preventative Medications Directly?
It is a common belief that patients with MOH rarely respond of preventative medications whilst overusing acute medications. However, no randomized trial has been done previously to prove such statement.
- Trial name
- NCT00159588
- Testing
- Betablockers or other preventive drugs based on primary headache type
- Where
- Norway
- Volunteers
- 64 people
- Sponsor
- Norwegian University of Science and Technology
Parkinson's Disease
Safety/Efficacy of Tigan® to Control Nausea/Vomiting Experienced During Apokyn® Initiation and Treatment
The purposes of the study are to determine: i. To assess the efficacy of Tigan® (trimethobenzamide) in preventing nausea and vomiting when initiating therapy with Apokyn® (apomorphine) ii.
- Trial name
- NCT00489255
- Testing
- Tigan®
- Where
- 27 sites in United States
- Volunteers
- 117 people
- Sponsor
- Ipsen
Neonatal Abstinence Syndrome
Clonidine to Treat Iatrogenic-induced Opioid Dependence in Infants
Thousands of critically ill infants (and children) are exposed to opioids and benzodiazepines to achieve sedation and analgesia as part of routine care in neonatal and pediatric intensive care units.
- Trial name
- NCT01360450
- Testing
- Clonidine HCL, saline
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Johns Hopkins University
Smoking
Functional Magnetic Resonance Imaging (fMRI) Investigation of Nicotine Withdrawal Symptoms
A single center, double blind, randomized, placebo controlled, two-treatments, two-period crossover study conducted in adult smokers.
- Trial name
- NCT00657020
- Testing
- Nicotine
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Parkinson Disease
Nabilone for Non-motor Symptoms in Parkinson's Disease
This is a randomized placebo-controlled, double-blind, parallel-group, enriched enrollment randomized withdrawal study assessing the efficacy and safety of nabilone for non-motor symptoms in patients with Parkinson´s Disease.
- Trial name
- NMS-Nab (NCT03769896)
- Testing
- Nabilone 0.25 mg
- Where
- Austria
- Volunteers
- 48 people
- Sponsor
- Medical University Innsbruck
Pro-opiomelanocortin (POMC) Deficiency Obesity
Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency Obesity
To demonstrate statistically significant and clinically meaningful effects of setmelanotide on percent body weight change in participants with pro-opiomelanocortin (POMC) deficiency or proprotein convertase subtilisin/kexin type…
- Trial name
- NCT02896192
- Testing
- Setmelanotide
- Where
- 7 sites in United States, Belgium and 5 more
- Volunteers
- 15 people
- Sponsor
- Rhythm Pharmaceuticals, Inc.
Opioid Abuse, Opioid Dependence
Effects of Ibudilast on Oxycodone Self-administration in Opioid Abusers
Opioid drugs increase glial cell activation which may be related to the abuse liability of opioid drugs. Data supporting this hypothesis have demonstrated that glial cell attenuators decrease the positive rewarding aspect of…
- Trial name
- NCT01740414
- Testing
- MN-166 (50 mg) First
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- New York State Psychiatric Institute
Pulmonary Disease, Chronic Obstructive
Inhaled Corticosteroid Withdrawal in Patients With Chronic Obstructive Pulmonary Disease
This is a randomised study to be conducted in patients with severe to very severe Chronic Obstructive Pulmonary Disease (COPD) to establish whether there is a need for these patients to be continuously treated with an inhaled…
- Trial name
- NCT00975195
- Testing
- tiotropium inhalation, salmeterol xinafoate, fluticasone propionate
- Where
- 222 sites in Australia, Belgium and 21 more
- Volunteers
- 2,488 people
- Sponsor
- Boehringer Ingelheim
Opioid Use Disorder
Impact of Bridge™ Device to Treat Opioid Withdrawal Symptoms
The purpose of this prospective study is to investigate the efficacy of the Bridge™ device in reducing the symptoms of opioid withdrawal in a blind comparison to a sham device.
- Trial name
- NCT05924945
- Testing
- Bridge™ active device
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Masimo Corporation
Familial Cold Autoinflammatory Syndrome (FCAS), Familial Cold Urticaria
Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
Inflammatory symptoms of Cryopyrin-Associated Periodic Syndrome (CAPS) are due to mutations in a the NLRP-3 gene (previously known as Cold Induced Autoinflammatory Syndrome-1 or CIAS1).
- Conditions
- Familial Cold Autoinflammatory Syndrome (FCAS), Familial Cold Urticaria, Muckle-Wells Syndrome (MWS), Genetic Diseases, Inborn
- Trial name
- NCT00288704
- Testing
- rilonacept 160 mg
- Where
- 24 sites in United States
- Volunteers
- 104 people
- Sponsor
- Regeneron Pharmaceuticals
Opioid Use Disorder
NET Device for Treating Opioid Use Disorder
This prospective, randomized, double-blind, parallel-group, sham-controlled, superiority study will evaluate the effectiveness of the NET Device in treating persons with Opioid Use Disorder (OUD) without use of Medications for…
- Trial name
- NCT04916600
- Testing
- NET
- Where
- United States
- Volunteers
- 108 people
- Sponsor
- Wayne State University
Major Depressive Disorder, Anxiety
Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms
The purpose of this study is to investigate the efficacy and safety of flexibly dosed adjunctive brexpiprazole treatment in subjects with major depressive disorder and anxiety symptoms, who are experiencing an inadequate…
- Trial name
- NCT02013531
- Testing
- Brexpiprazole
- Where
- 21 sites in United States
- Volunteers
- 37 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Bipolar I Disorder, Mania
A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features
1) To evaluate the efficacy and safety of cariprazine at a target dose of 3.0 mg/day compared with placebo in prevention of relapse in patients with bipolar I disorder whose current episode (i.e.
- Conditions
- Bipolar I Disorder, Mania, Depression
- Trial name
- NCT03573297
- Testing
- Cariprazine
- Where
- 108 sites in United States, Bulgaria and 9 more
- Volunteers
- 901 people
- Sponsor
- AbbVie
Alcohol Dependence, Bipolar Disorder
Acamprosate vs. Placebo in Bipolar Alcoholics
To conduct a double-blind, randomized, placebo-controlled outpatient clinical trial of acamprosate in individuals with alcohol dependence and bipolar disorder who are also receiving mood stabilizing medication.
- Trial name
- NCT00466661
- Testing
- Acamprosate
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Medical University of South Carolina
Mental and Behavioral Disorders, Withdrawal State
Effect of the Electronic Cigarette on Withdrawal Symptoms
Study rationale: Sensory/behavioural elements of smoking play a role in smoking behaviour and may have a potential to assist smoking cessation.
- Trial name
- ECIG24 (NCT01454362)
- Testing
- Nicotine
- Where
- United Kingdom
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Queen Mary University of London
Smoking Cessation
Assessing Neuropsychiatric Symptoms Including Depression, Anxiety, Irritability, and Suicidal Thoughts or Behavior in Subjects Quitting Smoking on Varenicline Tartrate or Placebo
Study objective is to compare neuropsychiatric adverse events in subjects treated with varenicline or placebo in a controlled setting where both groups are experiencing nicotine withdrawal.
- Trial name
- NCT00749944
- Testing
- varenicline
- Where
- 2 sites in United States
- Volunteers
- 110 people
- Sponsor
- Pfizer